Novartis has made kidney disorders an area of focus, and it’s now adding a new drug prospect through a deal to acquire Regulus Therapeutics, a biotech with a drug ready for pivotal testing in a rare ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...

MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as ...

In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, ...

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...

HealthTap launched a virtual care program to support sleep equipment suppliers and patients using PAP therapy.

Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out ...

Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah ...

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular ...

Vision products giant Alcon is expanding its offerings for the eyes through the $550 million acquisition of Neurotech Pharmaceuticals, a company that developed and commercialized the only FDA-approved ...

Rick Abramson, a radiologist by training and the director of FDA's Digital Health Center of Excellence said, "We ended up ...

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...